Oramed initiates Phase 3 oral insulin trials

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) began screening patients for its two Phase 3 trials evaluating ORMD-0801 for the treatment of Type 2 diabetes. The trials will enroll a total of 1,125 Type 2 diabetes patients...


Analysts start SQZ Biotechnologies at buy

Analysts with Stifel and BTIG launched coverage of SQZ Biotechnologies (NYSE:SQZ) with “buy” ratings and price targets of $38 and $40, respectively. The stock closed at $27.62 on Nov. 23. “We believe SQZ’s Cell Squeeze...


HCW starts Curis at buy; PT $5

H.C. Wainwright initiated coverage of Curis (NASDAQ:CRIS) with a “buy” rating and price target of $5. The stock closed at $1.35 on Nov. 23. Curis is developing two novel therapeutics for three potential indications that...

Orchard Therapeutics Logo

FDA clears Orchard Therapeutics IND for OTL-200

The FDA cleared Orchard Therapeutics’ (NASDAQ:ORTX) IND for OTL-200, a stem cell-based gene therapy for the treatment of metachromatic leukodystrophy (MLD). MLD is caused by a mutation in the arylsulfatase-A gene, which...

Eiger BioPharmaceuticals Logo

FDA approves Eiger’s Zokinvy for progeria

The FDA approved Eiger BioPharmaceuticals’ (NASDAQ:EIGR) Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies. Progeria is an extremely rare and fatal disease caused by a...

Biodesix Logo

Analysts start Biodesix at buy and OP

200 Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Biodesix (NASDAQ:BDSX) with “buy” and “outperform” ratings. Shares of Biodesix closed at $17.09 on Nov. 20. Canaccord analyst Max Masucci...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.